CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset.

导出原文传递

翻译打印收藏纠错

作者： Annett,Maderer ^[1] ; Frederic,Fiteni ^[2] ; Erik,Tanis ^[2] ; Murielle,Mauer ^[3] ; Thomas,Schmitt ^[1] ; Daniela E,Aust ^[4] ; Manfred P,Lutz ^[5] ; Felicitas,Roelofson ^[6] ; Christiane,Gog ^[7] ; Arndt,Weinmann ^[1] ; Claus H,Koehne ^[8] ; Markus,Moehler ^[1] ; Thomas,Thomaidis ^[1]

作者单位： Department of Internal Medicine, Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany. ^[1] Fellowship Programme Unit, EORTC Headquarters, Brussels, Belgium. ^[2] Statistics Department, EORTC Headquarters, Brussels, Belgium. ^[3] Molekulare/Prädiktive Diagnostik, Koordination UCC Tumor- und Normalgewebebank Institut für Pathologie, Dresden, Germany. ^[4] Caritas Klinikum Saarbrücken, Saarbrücken, Germany. ^[5] Evangel. Bethesda-Krankenhaus, Essen, Germany. ^[6] Klinikum der JW Goethe, Universität Frankfurt am Main, Frankfurt, Germany. ^[7] Department of Oncology and Hematology, Klinikum Oldenburg, European Medical School Oldenburg/Groningen, Carl von Ossietzky University Oldenburg, Oldenburg, Germany. ^[8] Second Department of Gastroenterology, Hygeia Hospital, Athens, Greece. ^[9]